Probiotics for Urinary Tract Infection

Specific lactobacillus strains that recolonise the vaginal microbiome show modest evidence for preventing recurrent UTI, though the effect is smaller than vaginal oestrogen or increased fluid intake.

Overview

Specific lactobacillus strains that recolonise the vaginal microbiome show modest evidence for preventing recurrent UTI, though the effect is smaller than vaginal oestrogen or increased fluid intake.

Verdict

Mixed evidence

A reasonable option for recurrent infection in women, using the specific strains studied. Useless for treating an active infection, which needs antibiotics.

How It Works

A lactobacillus-dominant vaginal microbiome produces lactic acid and hydrogen peroxide, maintaining a low pH that resists colonisation by uropathogenic E. coli from the perineal reservoir. Recurrent UTI is strongly associated with loss of this dominance, so reintroducing lactobacilli aims to restore colonisation resistance at the source rather than acting in the bladder.

Dosing & Protocol

Typical dose

Recommended dose: Lactobacillus crispatus or L. rhamnosus GR-1 with L. reuteri RC-14, oral or vaginal, daily
Expected timeframe: Judged over three to six months by counting recurrences, not by any acute symptom change.

Protocol

form: Vaginal suppository or oral capsule with urogenital strain data - general gut probiotics have no UTI evidence
duration: 3-6 months for recurrence prevention
co factor: This is prevention of recurrence, not treatment of an active infection. Evidence is mixed: L. crispatus vaginal suppositories reduced recurrence in one randomised trial, while other strains and oral routes showed no benefit and performed worse than antibiotic prophylaxis.
titration: Vaginal products are typically used nightly for one to two weeks then twice weekly; oral products once or twice daily
starting dose: An oral or vaginal product supplying 1-10 billion CFU of Lactobacillus crispatus, L. rhamnosus GR-1 or L. reuteri RC-14

Evidence

What the studies say

The most cited trial randomised women with recurrent UTI to intravaginal Lactobacillus crispatus or placebo and found a meaningful reduction in recurrence over ten weeks. Oral formulations of L. rhamnosus GR-1 with L. reuteri RC-14 have shown vaginal colonisation and some reduction in recurrence, though a comparison against trimethoprim-sulfamethoxazole found probiotics non-inferior on recurrence but without the resistance penalty, which is a clinically interesting trade-off. Cochrane reviews conclude the evidence is too heterogeneous and the trials too small to support routine use, and several negative studies exist, generally using strains without demonstrated vaginal colonisation. Context matters: vaginal oestrogen after menopause and increasing fluid intake by 1.5 litres daily both have stronger recurrence data than any probiotic.

No studies are yet linked to both Probiotics and Urinary Tract Infection.

Safety

Caveats

Strain specificity is critical, and most retail products contain strains never shown to colonise the vagina. Not a treatment for an active infection — delaying antibiotics risks pyelonephritis. Caution in severely immunocompromised patients.

Less likely to help if

Anyone with an active symptomatic infection, and postmenopausal women who have not yet tried vaginal oestrogen, which is more effective.

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.